Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy

Journal of Ethnopharmacology

Volumn 140, Issue 3, 2012, Pages 614-623

  Liu, Shwu Huey ^a   Cheng, Yung Chi ^b  

^a PhytoCeutica Inc   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer adjuvant; Capecitabine; Colorectal cancer; CPT 11; Hepatocellular carcinoma; Mechanism of action; Pancreatic cancer; PHY906

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; CLEVUDINE; ETOPOFOS; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HERBACEOUS AGENT; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PHY 906; REVOVIR; SORAFENIB; SUNITINIB; THALIDOMIDE; TROXACITABINE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MODEL; CANCER PATIENT; CHINESE MEDICINE; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; GLYCYRRHIZA URALENSIS; HAND FOOT SYNDROME; HERB; HUMAN; HYPERBILIRUBINEMIA; HYPONATREMIA; JUJUBE; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PAEONIA LACTIFLORA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCUTELLARIA BAICALENSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; STOMATITIS; TAIWAN; TUMOR XENOGRAFT; UNITED STATES; VOMITING;

GLYCYRRHIZA URALENSIS; PAEONIA LACTIFLORA; SCUTELLARIA BAICALENSIS; ZIZIPHUS JUJUBA;

EID: 84862777420     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2012.01.047     Document Type: Article

References (61)

1. Alsamarai, S., Ravage-Mass, L., Kaley, K., et al., 2010. A phase I study of PHY906 as a modulator of irinotecan (CPT-11) in patients with advanced solid tumors. Journal of Clinical Oncology 28 (suppl; abstr e13571).
2. Alsowmely, A.M., Hodgson, J.F., 2002. Review article: non-surgical treatment of hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 16, 1-15. (Pubitemid 34123859)
3. American Cancer Society, 2011. Cancer Facts and Figures. American Cancer Society, Atlanta, GA.
4. Armstrong, T.S., Gilbert, M.R., 2008. Use of complementary and alternative medical therapy by patients with primary brain tumors. Current Neurology and Neuroscience Reports 8, 264-268.
5. Berlin, J.D., Catalano, P., Thomas, J.P., et al., 2002. A 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. Journal of Clinical Oncology 20, 3270-3275. (Pubitemid 34831525)
6. Bleiberg, H., Cvitkovic, E., 1996. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective. European Journal of Cancer Prevention 32A, S18-S23.
7. Burris 3rd, H.A., Moore, M.J., Andersen, J., et al., 1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology 15, 2403-2413. (Pubitemid 27251144)
8. Calabresi, P., Chabner, B.A., 1996. Chemotherapy of neoplastic diseases. In: Goodman & Gilman's The Pharmocological Basis of Therapeutics, ninth Ed, Section X:1225-1232.
9. Chauffert, B., Mornex, F., Bonnetain, F., et al., 2008. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Annals of Oncology 19, 1592-1599.
10. Chen, K.F., Tai, W.T., Liu, T.H., et al., 2010. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clinical Cancer Research 16, 5189-5199.
11. Chen, S.T., Dou, J., Temple, R., et al., 2008. New therapies from old medicines. Nature Biotechnology 26, 1077-1083.
12. Chen, S.T., 2011. Regulation of research: is it a drug trial or a supplement trial? Fitoterapia 82, 14-16.
13. Cheng, A.L., Kang, Y.K., Chen, Z., et al., 2009. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology 10, 25-34.
14. Dolgin, E., 2011. When it takes two to tango, FDA suggests a new regulatory dance. Nature Medicine 17, 270.
15. Douillard, J.Y., Cunningham, D., Roth, A.D., et al., 2000. Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355, 1041-1047. (Pubitemid 30162806)
16. Eisenberg, D.M., Davis, R.B., Ettner, S.L., et al., 1998. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280, 1569-1575. (Pubitemid 28520643)
17. El-Serag, H.B., Mason, A.C., 1999. Rising incidence of hepatocellular carcinoma in the United States. New England Journal of Medicine 340, 745-750. (Pubitemid 29114292)
18. Farrell, M.P., Kummar, S., 2003. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clinical Colorectal Cancer 2, 253-256. (Pubitemid 36367315)
19. FDA. Guidance for Industry. Botanical Drug Products (FDA, DC, June 2004). http://www.fda.gov/cder/guidance/4592fnl.pdf.
20. Forman, W.B., 1994. The role of chemotherapy and adjuvant therapy in the management of colorectal cancer. Cancer 74, 2151-2153. (Pubitemid 24304387)
21. Goldber, R.M., Erlichman, C., 1988. Irinotecan plus FU and leucovorin in advanced colorectal cancer: North American trials. Oncology 12, 59-63.
22. Hoimes, C.J., Lamb, L., Ruta, S., et al., 2008. A phase I/II study of PHY906 plus capecitabine (CAP) in patients (pts) with advanced pancreatic cancer. Journal of Clinical Oncology 26 (May 20 suppl abstr 15538).
23. Karaca-Mandic, P., McCullough, J.S., Siddiqui, M.A., et al., 2011. Impact of new drugs and biologics on colorectal cancer treatment and costs. Journal of Oncology Practice 7, e30s-7s.
24. Konkimalla, V.B., Efferth, T., 2008. Evidence-based Chinese medicine for cancer therapy. Journal of Ethnopharmacology 116, 207-210.
25. Kummar, S., Copur, M.S., Rose, M., et al., 2011. A phase I study of the Chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clinical Colorectal Cancer 10, 85-96.
26. Lam, W., Leung, C.H., Jiang, Z., et al., 2007. Mechanisms of action of PHY-906 in enhancing anti-cancer drug actions of HepG2 implant nude mice. In: Proceedings of the Sixth Meeting of Consortium for Globalization of Chinese Medicine.
27. Lam, W., Bussom, S., Guan, F., et al., 2009. Exploration of the mechanisms of PHY906 in reducing the intestinal toxicity caused by irinotecan. In: Proceedings of American Association for Cancer Research. # 4584.
28. Lam, W., Bussom, S., Guan, F., et al., 2010. PHY906, a four-herb Chinese medicine formula first described 1800 years ago, reduces irinotecan-induced intestinal damage through anti-inflammatory effects and by promotion of the repopulation of intestinal progenitor cells. Science Translational Medicine 2, 45ra59.
29. Li, J., Merl, M.Y., Saif, M.W., 2010. Any second-line therapy for advanced pancreatic cancer? Highlights from the 2010 ASCO Gastrointestinal Cancers Symposium. Journal of Oncology Practice 11, 151-153.
30. Liu, S.H., Jiang, Z., Liddil, J., et al., 2000. Prevention of CPT-11 induced toxicity by a Chinese medicinal formulation, PHY-906. In: Proceedings of American Association for Cancer Research, vol. 41, p. 2608.
31. Liu, S.H., Jiang, Z., Cheng, Y.C., 2001. A Chinese medicine formulation, PHY-906, can enhance the therapeutic index of CPT-11 and other anticancer drugs against cancer in mice. In: Proceedings of American Association for Cancer Research. # 458.
32. Liu, S.H., Jiang, Z., Cheng, Y.C., 2002. Botanical activity relationship in traditional Chinese medicine: studies of PHY906 as an adjuvant therapy with cancer chemotherapeutic agents. In: Proceedings of American Association for Cancer Research, vol. 43, #4758.
33. Liu, S.H., Jiang, Z., Gao, W., et al., 2003. PHY906, a Chinese herbal formulation enhances the therapeutic effect of cancer chemotherapy in human colorectal and liver cancer. In: Proceedings of American Society of Clinical Oncology, #864.
34. Liu, S.H., Jiang, Z., Su, T.M., et al., 2004. Developing PHY906 as a broad-spectrum modulator of chemotherapeutic agents in cancer therapy. In: Proceedings of American Association for Cancer Research, #557.
35. Liu, S.H., Foo, A., Jiang, Z., et al., 2006. PHY906 as a broad-spectrum enhancer in cancer therapy: clinical and preclinical results in hepatocellular carcinoma. Proceedings of American Association for Cancer Research, # 2145.
36. Liu, S.H., Jiang, Z., Foo, A., et al., 2007. PHY906 in hepatocellular carcinoma. In: Proceedings of American Association for Cancer Research, # 1841.
37. Liu, S.H., Cheng, Y.C., Saif, M.W., 2010. Controlling chemotherapy-related side effects with Chinese medicine. In: Supportive Cancer Care with Chinese Medicine. Springer Science, Netherlands, Chapter 7, pp. 141-167.
38. Liu, S.H., Saif, M.W., 2012. Evidence-based anticancer materia medica for pancreatic cancer. In: Materia Medica for Various Cancers. Evidence-based Anticancer Complementary and Alternative Medicine. Springer Science, Netherlands, Chapter 11, pp. 211-228.
39. Llovet, J.M., Ricci, S., Mazzaferro, V., et al., 2008. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 359, 378-390.
40. Marcus, D.M., Grollman, A.P., 2002. Botanical medicines - the need for new regulations. New England Journal of Medicine 347, 2073-2076. (Pubitemid 35461667)
41. Quimby, E.L., 2007. The use of herbal therapies in pediatric oncology patients: treating symptoms of cancer and side effects of standard therapies. Journal of Pediatric Oncology Nursing 24, 35-40. (Pubitemid 44954360)
42. Ozols, R.F., Herbst, R.S., Colson, Y.L., et al., 2007. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. Journal of Clinical Oncology 25, 146-162. (Pubitemid 350003060)
43. Rose, M., Yen, Y., So, S., et al., 2007. Phase I/II study of PHY906/capecitabine in hepatocellular carcinoma. In: Proceedings of American Society of Clinical Oncology # 15152.
44. Rothenberg, M.L., Cox, J.V., DeVore, R.F., 1999. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85, 786-795.
45. Saif, M.W., Liu, S., Elfiky, A., et al., 2007. Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma. In: Proceedings of American Society of Clinical Oncology, # 15116.
46. Saif, M.W., 2008a. Is there a standard of care for the management of advanced pancreatic cancer? Highlights from the Gastrointestinal Cancers Symposium, January 25-27, Orlando, FL, USA. Journal of the Pancreas 9 (2), 91-98. (Pubitemid 351611724)
47. Saif, M.W., 2008b. Is there a role for herbal medicine in the treatment of pancreatic cancer? Highlights from the 44th ASCO Annual Meeting. Journal of the Pancreas 9 (4), 403-407.
48. Saif, M.W., Lamb, L., Li, J., et al., 2008. Phase I/II study of PHY906 plus Capecitabine (CAP) in patients with gemcitabine-refractory pancreatic cancer (PC). Proceedings of 7th meeting of Consortium for Globalization of Chinese Medicine.
49. Saif, M.W., Li, J., Lamb, L., et al., 2009. A phase II study of capecitabine (CAP) plus PHY906 in Pts with advanced pancreatic cancer (APC). In: Proceedings of American Society of Clinical Oncology, # e15508.
50. Saif, M., Li, J., Lamb, L., et al., 2010a. Phase II study of PHY906 plus capecitabine (CAP) in pts with gemcitabine-refractory pancreatic cancer (PC) and measurement of cytokines. Journal of Clinical Oncology 28 (suppl; abstr e14540).
51. Saif, M.W., Lansigan, F., Ruta, S., et al., 2010b. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies? Phytomedicine 17 (3-4), 161-169.
52. Saltz, L.B., Cox, J.V., Blanke, C., et al., 2000. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 343, 905-914.
53. Saltz, L.B., Niedzwiecki, D., Hollis, D., et al., 2007. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. Journal of Clinical Oncology 25 (23), 3456-3461. (Pubitemid 47310883)
54. Sandhu, D.S., Tharayil, V.S., Lai, J.P., et al., 2008. Treatment options for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2 (1), 81-92.
55. Tilton, R., Paiva, A.A., Guan, J.Q., et al., 2010. A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906. Chinese Medicine 5, 30.
56. Wang, E., Bussom, S., Gen, J., et al., 2011. Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC Medical Genomics 4, 38.
57. Wong, R., Sagar, C.M., Sagar, S.M., 2001. Integration of Chinese medicine into supportive cancer care: A modern role for an ancient tradition. Cancer Treatment Reviews 27, 235-246. (Pubitemid 32851176)
58. Wu, K.M., Farrelly, J., Birnkrant, D., et al., 2004. Regulatory toxicology perspectives on the development of botanical drug products in the United Sates. American Journal of Therapeutics 11, 213-217.
59. Ye, M., Liu, S.H., Jiang, Z., et al., 2007. Liquid chromatography/mass spectrometry analysis of PHY906, a Chinese medicine formulation for cancer therapy. Rapid Communications in Mass Spectrometry 21, 3593-3607. (Pubitemid 350124627)
60. Yen, Y., So, S., Rose, M., et al., 2009. Phase I/II study of capecitabine and PHY906 in hepatocellular carcinoma. Anticancer Research 29, 4083-4092.
61. Zhang, W., Saif, M.W., Dutschman, G.E., et al., 2010. Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). Journal of Chromatography A 1217, 5785-5793.